The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.

2020 Recap by Yannis Jemiai, Chief Scientific Officer, Cytel

December 17, 2020

As Chief Scientific Officer, Dr. Yannis Jemiai plays a pivotal role in maintaining Cytel’s well-established reputation for statistical excellence and our track-record of bringing innovative analytic approaches to the development of medicines for human health. In this blog, we ask Yannis for his favorite Cytel events from 2020.

Read More

2020 Recap by Pantelis Vlachos, Principal/Strategic Consultant, Cytel

December 16, 2020

As we prepare to close the door on 2020, we asked Pantelis Vlachos, Principal/Strategic Consultant for Cytel, to share his favorite Cytel events of this year. Continue reading this blog for a summary of Cytel’s 2020 contributions around adaptive designs and Bayesian methods.

Read More

Bayesian Methods for Multiple Cohort Expansion (MuCE) designs

November 16, 2020

MUCE is a Bayesian solution for cohort expansion trials where multiple dose(s) and multiple indication(s) are tested in parallel. Such methods are particularly important for areas like oncology where several doses and several indications must be tested for successful completion of early phase trials, and optimal choice of dose and population to move on from early phase to a reasonable dosage for Phase 3.

Note that for these situations the number of comparator arms for a trial can increase rather rapidly. Testing three doses with three indications essentially requires 9 different trials. An efficient way to test a higher number of trials is therefore necessary for accelerated clinical development.

Read More